VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using iso...

Popoln opis

Bibliografske podrobnosti
Main Authors: Varey, A, Rennel, E, Qiu, Y, Bevan, H, Perrin, R, Raffy, S, Dixon, A, Paraskeva, C, Zaccheo, O, Hassan, A, Harper, S, Bates, DO
Format: Journal article
Jezik:English
Izdano: 2008

Podobne knjige/članki